The abstract reports that chronic DMF treatment increased hemoglobin F levels, but provides no mechanistic explanation for how Nrf2 activation leads to fetal hemoglobin induction. This represents an unexpected therapeutic effect that could have major clinical implications for sickle cell treatment. Gap type: unexplained_observation Source paper: Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate. (2017, Antioxidants & redox signaling, PMID:26914345)
Landscape Summary: What mechanisms explain DMF's increase in hemoglobin F production in sickle cell disease? is a 0.85 priority gap in hematopoiesis. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What mechanisms explain DMF's increase in hemoglobin F production in sickle cell disease? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: